Condition | ACh | Emax relaxation | n |
SAH day 3 with LV 10−4 M | 10−8 M | 31%±21%*† | 8 |
10−7 M | 50%±31%*† | 8 | |
10−6 M | 65%±38% | 8 | |
10−5 M | 64%±32% | 8 | |
10−4 M | 73%±30% | 8 | |
Emax | 76%±34% | ||
SAH day 5 with LV 10−4 M | |||
10−8 M | 20%±11% | 8 | |
10−7 M | 40%±22% | 8 | |
10−6 M | 55%±24% | 8 | |
10−5 M | 75%±15% | 8 | |
10−4 M | 77%±16% | 8 | |
Emax | 79%±13% |
ACh triggered a dose-dependent vasorelaxation, which was strongly and dose-dependent enhanced by prior incubation with LV. Values are expressed as mean±SD.
*P<0.05 vs solvent control.
†P<0.05 vs sham LV 10−5 M.
ACh, acetylcholine; LV, levosimendan; SAH, subarachnoid hemorrhage.